Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.

Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H.

J Neurosci. 2006 Sep 27;26(39):10068-78.

2.

Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.

van Rooijen BD, Claessens MM, Subramaniam V.

Curr Protein Pept Sci. 2010 Aug;11(5):334-42. Review.

PMID:
20423294
3.

Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.

Paleologou KE, Irvine GB, El-Agnaf OM.

Biochem Soc Trans. 2005 Nov;33(Pt 5):1106-10. Review.

PMID:
16246056
4.

The aggregation and fibrillation of alpha-synuclein.

Fink AL.

Acc Chem Res. 2006 Sep;39(9):628-34. Review.

PMID:
16981679
5.

Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease.

Angot E, Brundin P.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S143-7. doi: 10.1016/S1353-8020(09)70802-8. Review.

PMID:
20082977
6.

Oxidative modifications of alpha-synuclein.

Ischiropoulos H.

Ann N Y Acad Sci. 2003 Jun;991:93-100. Review.

PMID:
12846977
7.

The relevance of iron in the pathogenesis of Parkinson's disease.

Götz ME, Double K, Gerlach M, Youdim MB, Riederer P.

Ann N Y Acad Sci. 2004 Mar;1012:193-208. Review.

PMID:
15105267
8.

The remarkable conformational plasticity of alpha-synuclein: blessing or curse?

Deleersnijder A, Gerard M, Debyser Z, Baekelandt V.

Trends Mol Med. 2013 Jun;19(6):368-77. doi: 10.1016/j.molmed.2013.04.002. Epub 2013 May 3. Review.

PMID:
23648364
9.

Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation.

Goodwin J, Nath S, Engelborghs Y, Pountney DL.

Neurochem Int. 2013 Apr;62(5):703-11. doi: 10.1016/j.neuint.2012.11.004. Epub 2012 Nov 15. Review.

PMID:
23159813
10.

Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications.

Ottolini D, Calí T, Szabò I, Brini M.

Biol Chem. 2017 Jan 1;398(1):77-100. doi: 10.1515/hsz-2016-0201. Review.

PMID:
27508962
11.

Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers.

Beyer K.

Acta Neuropathol. 2006 Sep;112(3):237-51. Epub 2006 Jul 15. Review.

PMID:
16845533
12.

Interactions between calcium and alpha-synuclein in neurodegeneration.

Rcom-H'cheo-Gauthier A, Goodwin J, Pountney DL.

Biomolecules. 2014 Aug 14;4(3):795-811. doi: 10.3390/biom4030795. Review.

13.

Chaperone-mediated autophagy in aging and neurodegeneration: lessons from alpha-synuclein.

Bandyopadhyay U, Cuervo AM.

Exp Gerontol. 2007 Jan-Feb;42(1-2):120-8. Epub 2006 Jul 24. Review. Erratum in: Exp Gerontol. 2008 Sep;43(9):872. Bandhyopadhyay, Urmi [corrected to Bandyopadhyay, Urmi].

PMID:
16860504
14.

The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Lashuel HA, Overk CR, Oueslati A, Masliah E.

Nat Rev Neurosci. 2013 Jan;14(1):38-48. doi: 10.1038/nrn3406. Review.

15.

[Role of septin cytoskeleton in dopaminergic neurotransmission and neurodegeneration].

Kinoshita M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):25-9. Review. Japanese.

PMID:
22568123
16.

Alpha-synuclein and dopamine metabolism.

Yu S, Uéda K, Chan P.

Mol Neurobiol. 2005;31(1-3):243-54. Review.

PMID:
15953825
17.

Untangling the Manganese-α-Synuclein Web.

Peres TV, Parmalee NL, Martinez-Finley EJ, Aschner M.

Front Neurosci. 2016 Aug 4;10:364. doi: 10.3389/fnins.2016.00364. eCollection 2016. Review.

Supplemental Content

Support Center